Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome
F. Child, P.L. Ortiz-Romero, R. Alvarez, M. Bagot, R. Stadler, M. Weichenthal, R. Alves, P. Quaglino, M. Beylot-Barry, R. Cowan, L.J. Geskin, A. Pérez-Ferriols, P. Hellemans, Y. Elsayed, C. Phelps, A. Forslund, M. Kamida and P.L. Zinzani
Version of Record online: 2 JUN 2016 | DOI: 10.1111/bjd.14427
What's already known about this topic?
- Histone deacetylase inhibitors (HDAC-Is) have been associated with significant clinical activity in different neoplastic disorders. Vorinostat and romidepsin have been approved by the U.S. Food and Drug Administration for treatment of cutaneous T-cell lymphoma (CTCL).
- Quisinostat is a hydroxamate, second-generation, orally available pan-HDAC-I.
What does this study add?
- Oral quisinostat 12 mg three times weekly is active in the treatment of patients with relapsed or refractory CTCL, and has an acceptable safety profile.
- There was a low global response rate of 8% vs. a cutaneous response rate of 24%.
- Combination therapy of quisinostat with other novel agents may be appropriate in patients who relapse following current conventional approaches.